34 citations
,
April 2008 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.
27 citations
,
August 2010 in “Clinics in Dermatology” This article reviews the association between hepatitis C virus and systemic disorders like mixed cryoglobulinemia, highlighting potential autoimmune side effects from interferon-a2b treatments, and reports no new clinical results.
23 citations
,
January 2009 in “Veterinary Dermatology” This study found that recombinant hepatitis B vaccine may increase the risk of alopecia areata onset in older predisposed mice but larger trials suggest this effect might lie within normal variation.
8 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.
5 citations
,
March 2021 in “Hepatitis Monthly” This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.